Biotech Values

[DewDiligence]

...over time and multiple switches you might develop neutralizing antibodies that might reduce efficacy. So it's less of a concern with say Lovenox than it would be with say the RA biologics that patients are going to be on for years.

Whether antibodies to such drugs as the TNF-a class are problematic in a practical sense is controversial—see, for instance, #msg-61989536.